INTRAVENOUS METHYLPREDNISOLONE VS ORAL PREDNISOLONE IN TRANSPLANT REJECTION

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。比较静脉注射甲泼尼龙与口服泼尼松龙治疗小儿肝移植受者急性排斥反应的试验仍在继续。我们正在比较口服和静脉注射类固醇的效果，以提高患者的生活质量，降低医疗费用。过去，所有肝移植后发生急性排斥反应的儿童都需要住院一周。这会扰乱他们的日常生活，并对医疗费用产生影响。口服类固醇的生物利用度与静脉注射类固醇的生物利用度相似，因此我们假设两种治疗方法都有效。为了确保患者的安全，我们开始了这项小型研究来验证这一假设。我们的研究终点是急性排斥反应的控制，通过结果问卷评估的生活质量的改善和医疗费用的降低。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The trial comparing intravenous methlyprednisolone versus oral prednisolone in the treatment of acute rejection in pediatric liver transplant recipients continues. We are comparing the effect of oral versus iv steroids in an effort to improve the patients quality of life and to reduce medical costs. In the past, all children who had acute rejection following liver transplantation required one week hospitalization. This is disruptive to their day to day life and has an impact on medical costs. The bioavailability of orally administered steroids is similar to those given intravenously therefore we hypothesized both treatments are effective. To ensure patient safety, we began this small study to test that hypothesis. Our study endpoints are control of acute rejection, improved quality of life as assessed by an outcomes questionnaire and decreased medical cost.